Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia

W William G. Wierda (The University of Texas MD Anderson Cancer Center, Houston, Texas, United States) C Ching Ching Leow (21Eli Lilly and Company, Indianapolis, United States) A Amy S. Ruppert (William G. Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Ching Ching Leow, MD, Amy S. Ruppert, PhD, and Yuanyuan Bian, PhD, Eli Lilly and Company, Indianapolis, IN; and Jennifer A. Woyach, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH) Y Yuanyuan Bian (21Eli Lilly and Company, Indianapolis, United States) J Jennifer A. Woyach (5Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH)

Article Details

Volume / Issue Vol. 44, Issue 19
Published July 01, 2026
Pages 1847-1851
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (5)

W

William G. Wierda

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

C

Ching Ching Leow

21Eli Lilly and Company, Indianapolis, United States

A

Amy S. Ruppert

William G. Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Ching Ching Leow, MD, Amy S. Ruppert, PhD, and Yuanyuan Bian, PhD, Eli Lilly and Company, Indianapolis, IN; and Jennifer A. Woyach, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Y

Yuanyuan Bian

21Eli Lilly and Company, Indianapolis, United States

J

Jennifer A. Woyach

5Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH